In Vivo Antifungal Activity and Computational Studies of Some Azole Derivatives against Candida Albicans

Table 5

Absorption and distribution profile of all azole derivatives (1–15).

Entry	HIA	Caco-2 permeability	BBB	P-glycoprotein	Plasma protein binding (PPB)	Skin
1	84.40	0.58	0.01	NS/I	82.16	−4.02
2	75.36	1.2	0.05	NS/I	76.23	−4.04
3	92.91	6.91	0.07	NS/I	88.69	−3.58
4	89.23	6.89	0.05	NS/I	83.50	−3.87
5	86.45	7.47	0.06	NS/I	81.10	−3.67
6	74.93	3.36	0.08	NS/NI	69.23	−3.63
7	93.50	26.69	0.03	NS/NI	27.79	−4.2
8	94.75	26.33	0.05	NS/NI	43.43	−3.86
9	93.48	20.57	0.06	NS/NI	23.41	−4.15
10	94.15	23.50	0.05	NS/NI	33.55	−3.95
11	93.47	22.79	0.03	NS/NI	24.78	−3.93
12	100.0	57.02	1.85	NS/NI	96.14	−2.23
13	100.0	53.04	4.41	NS/I	94.37	−2.32
14	100.0	44.32	1.90	NS/I	100.0	−2.37
15	99.04	56.38	5.33	NS/I	98.69	−2.38
Fluconazole	95.58	17.23	0.24	NS/NI	55.15	−4.18

NS = nonsubstrate; NI = noninhibitor; S = substrate; I = Inhibitor.